medrxiv.org
Efficacy and safety of esketamine for treatment resistant depression: registered report for a Systematic Review with an Individual Patient Data Meta-analysis of Randomized, Double-Blind, Placebo-Contr...
Background In 2019, the FDA and EMA approved intranasal esketamine for treatment resistant depression (TRD). The current study re–evaluated its efficacy and safety. Methods This registered report pres...